SAN FRANCISCO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Life360, Inc. (Nasdaq: LIF; ASX: 360), the leading family safety and location services company, will release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 (U.S. PT) / Friday, February 28, 2025 (AEDT).

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –

Share price rose about 19% in the past year from $8.59 to $10.21, as of Friday’s market close.

President Donald Trump's pledge to impose sweeping tariffs on imports from Taiwan is raising concerns across semiconductor and pharmaceutical industries, particularly affecting Taiwan Semiconductor Manufacturing Co., the world's largest contract chipmaker.

Highlights

MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.

HOUSTON and LONDON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQBKR), an energy technology company, announced Monday an order from Bechtel Energy Inc. (Bechtel) to supply gas technology equipment for two liquefaction plants with a total capacity of approximately 11 MTPA for Phase 1 of Woodside Energy Group Ltd’s (ASX: WDS; NYSE: WDS) (Woodside) Louisiana LNG development opportunity. The order marks a significant milestone as Woodside targets final investment decision (FID) readiness from the first quarter of 2025.

ASE Technology Holding Co., Ltd. (ASE, TAIEX: 3711, NYSE: ASX), the leading provider of semiconductor packaging, test, and system assembly services, today announced that it has been recognized for its remarkable ESG performance with an inclusion on the 2024 Dow Jones Sustainability Indices (DJSI) World and Emerging Markets. The DJSI are float-adjusted market capitalization weighted indices that measure the performance of companies selected using environmental, social and governance (ESG) criteria. This year, 71 large cap companies were assessed in the Semiconductors and Semiconductor Equipment Industry Group for eligibility to be included on the 2024 DJSI World and only 8 including ASE successfully made the cut. This marks the ninth consecutive year that ASE has made the list.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders –

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Attributes 278% revenue growth to continued focus and execution of key strategic growth pillars

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024.

Monthly Active Users Reached Approximately 76.9 million for the QuarterRecord Global Net Additions to Paying Circles of 159 thousand - Reaching Nearly 2.2 million TotalTotal Revenue Grew 18% Year-Over-Year to $92.9 million Annualized Monthly Revenue increased 30% Year-Over-Year to $336.2 millionRaising Outlook for 2024 Adjusted EBITDA

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System.

ISE Labs, Inc., a leading provider of semiconductor engineering services, today announced the acquisition of a significant parcel of land within Axis 2 Industrial Park, located in Tonalá, a city and municipality within the Guadalajara Metropolitan Area. This strategic land purchase demonstrates the company’s long-term commitment to the state of Jalisco and establishes a footprint for future expansion.

– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –

Highlights

Advanced Semiconductor Engineering, Inc. (ASE, a member of ASE Technology Holding Inc, NYSE: ASX, TWSE: 3711) today announced it has been honored with a prestigious Gold Award at the 2024 PwC Sustainability Impact Awards for its marine conservation film, Guardians of the Sea. Produced by ASE Corporate Communications Team in collaboration with ASE Environmental Protection and Sustainability Foundation, the film highlights ASE’s innovative approach to marine conservation and environmental stewardship, captivating global judges with its creative and compelling portrayal of the company’s sustainability initiatives and social impact.

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial

Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.